{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-189147","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.245173+00:00","generated_at":"2026-06-13T06:14:40.557252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elevance Health Q2 GAAP EPS $7.79, adj. EPS $9.04; raises FY2023 guidance","bullets":["Q2 GAAP net income $7.79/sh, adjusted $9.04/sh; operating revenue $43.4B (+12.7% YoY).","Medical enrollment 48.0M, up 938k YoY; benefit expense ratio improved 70 bps to 86.4%.","Health Benefits operating gain $2.1B (+21% YoY); Carelon operating gain $632M (+6.8%).","Raises FY2023 outlook: GAAP EPS >$29.09, adjusted >$32.85.","Declares Q3 dividend $1.48/sh; repurchased 1.4M shares for $646M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-189147","json":"https://secwatch.observer/filing/0001193125-23-189147.json","markdown":"https://secwatch.observer/filing/0001193125-23-189147.md","text":"https://secwatch.observer/filing/0001193125-23-189147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000119312523189147/0001193125-23-189147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000119312523189147/d528939d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:14:40.557252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b906ceadbba79c2b5e0c99062dfc4c4e55f316c","claim":"Elevance Health, Inc. reported 2023 results: EPS GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share. Guidance raised.","evidence_excerpt":"Given the strong performance in the first half of the year and momentum across Elevance Health, we now expect GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312523189147/0001193125-23-189147-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"EPS","value":"GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a06f419248cd973ab803f143eb21ba1d2b725963","claim":"Elevance Health, Inc. reported the quarter ended June 30, 2023 results: revenue $43.4 billion, EPS $7.79 per share.","evidence_excerpt":"Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* per share. • Operating revenue grew 12.7% year-over-year to $43.4 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312523189147/0001193125-23-189147-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$43.4 billion"},{"label":"EPS","value":"$7.79 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}